CureVac seeks Covid-19 shot approval in Switzerland
Switzerland has already placed orders for five million doses of CureVac’s mRNA vaccine.
Keystone / Jeroen Jumelet
German drugmaker CureVac has submitted an application for the approval of its Covid-19 mRNA vaccine with Swiss drugs regulator Swissmedic. Until now Switzerland has approved three vaccines, two of which are being used.
Switzerland has already placed orders for five million doses of CureVac’s mRNA vaccine, which is similar to those from Moderna and Pfizer that are already being administered across the country.
The submission is part of a rolling review procedure to “evaluate the scientific data as soon as they become available”, Swissmedic said.
“CureVac can forward documentation on its vaccine candidate on an ongoing basis without having to await the final results of the clinical trials,” it said. However, it is unclear how long the review will take.
“The duration of the rolling review will depend on the completeness of the data submitted by CureVac and the results of the clinical trials, and cannot therefore be predicted,” Swissmedic said.
Swiss drugmaker Novartis has agreed to help make CureVac’s vaccine at a plant in neighbouring Austria.
AstraZeneca status
Although AstraZeneca was the first company to start the review process in Switzerland in early October for its vaccine, regulators have said they still don’t have enough information to approve the British company’s shot.
Swiss authorities have ordered nearly 36 million vaccine doses from Pfizer/BioNTech (6 million), Moderna (13.5 million), AstraZeneca (5.3 million), CureVac (5 million) and Novavax (6 million) for the population of 8.6 million people. So far, there are two vaccines approved and available in the country, those from Pfizer/BioNTech and Moderna. Johnson & Johnson’s single-dose vaccine has also been approved but has not been ordered by the Federal Office of Public Health. Others should follow.
Since January 4 (vaccinations began in late December) the government has started to roll out its vaccination planExternal link. It has set an ambitious target: to inoculate six million people or 70% of the population – on a voluntary basis – by summer, or up to 70,000 vaccine shots per day. The vaccination roll-out is being slowly scaled up. The programme has been delayed by vaccine production and delivery problems.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
This content was published on
The cantonal parliament of Vaud has approved a loan of CHF9.5 million ($11.5 million) for Château de Chillon, the most-visited monument in Switzerland.
Swiss party president Thierry Burkart to step down in October
This content was published on
Thierry Burkart, president of the centre-right Radical-Liberal Party, wants to hand over the presidency in October, around two years before the next national elections.
Climate Alliance presents action plan on 20th anniversary
This content was published on
The Swiss Climate Alliance has presented an action plan showing how Switzerland could make a success of the energy transition and achieve a net zero balance within ten years.
Swiss business group expects export slump after strong start to year
This content was published on
The Swiss economy was still robust in the first quarter of 2025 but is coming under increasing pressure, says the Swiss business federation, economiesuisse.
Five arrested in Switzerland in human-trafficking raid
This content was published on
Law enforcement authorities in Switzerland and Romania have busted a human trafficking ring. They arrested a total of 17 suspects.
OECD significantly lowers Swiss GDP forecast due to Trump
This content was published on
The Swiss economy is likely to grow more slowly in 2025 and 2026 than previously assumed, according to the OECD economic organisation.
UBS economists more confident about Swiss economy in 2025
This content was published on
UBS economists have revised upwards their estimates of Swiss GDP growth for the current year. However, they are more pessimistic for next year, due to the spectre of US tariffs.
Data on AstraZeneca vaccine insufficient for Swiss approval
This content was published on
Swissmedic says it has not yet received enough robust data from clinical trials to give the green light to the Covid-19 vaccine.
This content was published on
Media reports indicate that vaccinating everyone who wants to by summer relies on meeting ambitious vaccine delivery targets in spring.
Covid-19 vaccine: Why we still have a long wait ahead
This content was published on
Countries have started rolling out a Covid-19 vaccine, but it will likely take years to manufacture doses at the scale needed to reach the masses.
Swiss regulator warns of fake Covid-19 vaccines online
This content was published on
Scammers are selling dangerous fake coronavirus vaccines on the internet, Switzerland’s health regulator Swissmedic warned on Tuesday.
Swiss factory rushes to prepare for Moderna Covid-19 vaccine
This content was published on
Workers are racing to set up production lines at the Lonza factory in Visp to be able to start making a vaccine for US firm Moderna later this year.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.